Yvonne Greenstreet Sells 9,577 Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CEO Yvonne Greenstreet sold 9,577 shares of the stock in a transaction on Monday, January 12th. The shares were sold at an average price of $362.86, for a total transaction of $3,475,110.22. Following the transaction, the chief executive officer owned 78,411 shares in the company, valued at $28,452,215.46. This trade represents a 10.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Yvonne Greenstreet also recently made the following trade(s):

• On Thursday, November 13th, Yvonne Greenstreet sold 10,000 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $451.27, for a total transaction of $4,512,700.00.
• On Wednesday, November 12th, Yvonne Greenstreet sold 15,650 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $453.69, for a total value of $7,100,248.50.

Alnylam Pharmaceuticals Stock Down 0.8%

NASDAQ ALNY traded down $3.10 on Wednesday, hitting $366.86. 1,250,033 shares of the stock traded hands, compared to its average volume of 1,593,122. The company has a current ratio of 2.54, a quick ratio of 2.49 and a debt-to-equity ratio of 4.45. The stock has a 50-day moving average of $423.39 and a 200 day moving average of $421.94. Alnylam Pharmaceuticals, Inc. has a twelve month low of $205.87 and a twelve month high of $495.55. The company has a market capitalization of $48.47 billion, a P/E ratio of 1,528.58 and a beta of 0.32.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on ALNY shares. Stifel Nicolaus boosted their target price on shares of Alnylam Pharmaceuticals from $495.00 to $508.00 and gave the company a “buy” rating in a research note on Thursday, December 11th. Jefferies Financial Group lowered their price objective on shares of Alnylam Pharmaceuticals from $550.00 to $549.00 and set a “buy” rating for the company in a research report on Thursday, October 30th. Wells Fargo & Company raised their target price on shares of Alnylam Pharmaceuticals from $395.00 to $479.00 and gave the stock an “equal weight” rating in a report on Tuesday, November 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Alnylam Pharmaceuticals in a report on Wednesday, October 8th. Finally, Needham & Company LLC increased their price target on Alnylam Pharmaceuticals from $520.00 to $529.00 and gave the stock a “buy” rating in a research report on Monday. Twenty-two analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $490.96.

More Alnylam Pharmaceuticals News

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Needham & Company reiterated a bullish outlook and forecasted strong price appreciation for ALNY, giving investors a counterpoint to bearish views and providing potential support for the stock. Needham Bullish Forecast
• Positive Sentiment: Alnylam presented at the J.P. Morgan Healthcare Conference (transcript available) — management used the forum to outline development priorities and the Alnylam 2030 growth plan, keeping the company in front of institutional investors. JPM Presentation Transcript
• Neutral Sentiment: Analysis pieces are digesting the Alnylam 2030 plan and new 2026 guidance; valuation write-ups provide scenarios but do not change fundamentals immediately. These pieces are useful for longer-term investors assessing the plan vs. current multiples. Valuation After 2030 Plan
• Neutral Sentiment: CEO interviews and conference coverage (video/interview links) elaborate on development goals and timelines; useful for due diligence but contain no immediate new financials. CEO Interview
• Neutral Sentiment: Industry roundups from JPM/BioWorld reference Alnylam within broader biopharma Q4 revenue and guidance commentary — helpful context but not company-specific catalysts. Bioworld JPM Coverage
• Neutral Sentiment: Reported short-interest data appears anomalous (shows zero shares and NaN changes), so it should not be treated as signal until corrected by exchanges. No link (data issue)
• Negative Sentiment: Insider selling: CEO Yvonne Greenstreet and multiple EVPs sold shares on Jan 12–13 (CEO sale ~9,577 shares; several EVPs sold 1,510–2,780 shares each). Collectively these disclosed sales totaled roughly $7M, which markets often view as a near-term negative signal even if sales are for personal/diversification reasons. CEO SEC Filing
• Negative Sentiment: Bank of America published a pessimistic price forecast for ALNY, which can weigh on sentiment among institutional and retail investors. BofA Pessimistic Forecast
• Negative Sentiment: News coverage highlighted a sharp intraday sell-off (article noting ~9% drop) after the company unveiled ambitious 2026 guidance and its Alnylam 2030 plan — the market appears to be re-pricing risk around execution and near-term guidance. Coverage of the Sell-off

Institutional Trading of Alnylam Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the stock. OFI Invest Asset Management boosted its position in shares of Alnylam Pharmaceuticals by 5.8% in the 3rd quarter. OFI Invest Asset Management now owns 403 shares of the biopharmaceutical company’s stock valued at $184,000 after purchasing an additional 22 shares during the period. Howard Capital Management Inc. raised its holdings in Alnylam Pharmaceuticals by 2.9% during the 3rd quarter. Howard Capital Management Inc. now owns 854 shares of the biopharmaceutical company’s stock worth $389,000 after buying an additional 24 shares during the period. Frank Rimerman Advisors LLC lifted its stake in Alnylam Pharmaceuticals by 2.0% during the third quarter. Frank Rimerman Advisors LLC now owns 1,251 shares of the biopharmaceutical company’s stock valued at $570,000 after buying an additional 24 shares in the last quarter. Coastal Bridge Advisors LLC boosted its holdings in shares of Alnylam Pharmaceuticals by 2.3% in the third quarter. Coastal Bridge Advisors LLC now owns 1,097 shares of the biopharmaceutical company’s stock worth $500,000 after buying an additional 25 shares during the period. Finally, Meridian Financial Advisors LLC boosted its holdings in shares of Alnylam Pharmaceuticals by 3.5% in the third quarter. Meridian Financial Advisors LLC now owns 828 shares of the biopharmaceutical company’s stock worth $378,000 after buying an additional 28 shares during the period. 92.97% of the stock is owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.